Literature DB >> 29898864

Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension.

Satoshi Akagi1, Hiromi Matsubara2, Kazufumi Nakamura3, Hiroshi Ito3.   

Abstract

Treatment goals in pulmonary arterial hypertension (PAH) include improved quality of life and exercise capacity as well as improved life prognosis. In our experience, only remarkable reductions in pulmonary arterial pressure (PAP) improve long-term survival. Lowering PAP could contribute to reverse remodeling by reducing hemodynamic stress. Proper and prompt use of PAH-specific drugs lowers PAP in patients with PAH. Upfront combination therapy with different PAH-specific drugs and quickly establishing high-dose epoprostenol lowers PAP sufficiently to improve prognosis in patients with PAH. PAH is often a comorbidity with other diseases including congenital heart defect, connective tissue diseases, and pulmonary arterial aneurysm. It is essential in these conditions to lower PAP to allow the next treatment strategy. In this report, we review modern treatments to lower PAP in patients with PAH.
Copyright © 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Combination therapy; Lowering pulmonary artery pressure; Pulmonary arterial hypertension; Quickly establishing high-dose epoprostenol therapy

Mesh：

Substances：

Year:  2018        PMID： 29898864     DOI： 10.1016/j.jjcc.2018.04.014

Source DB:  PubMed          Journal:  J Cardiol        ISSN： 0914-5087            Impact factor:   3.159


  7 in total

1.  Improvement of lung function and pulmonary hypertension after pulmonary aneurysm repair: case series.

Authors:  Satoshi Akagi; Kentaro Ejiri; Shingo Kasahara; Kazufumi Nakamura; Hiroshi Ito
Journal:  Pulm Circ       Date:  2019 Jan-Mar       Impact factor: 3.017

Review 2.  Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension.

Authors:  Kazufumi Nakamura; Satoshi Akagi; Kentaro Ejiri; Masashi Yoshida; Toru Miyoshi; Norihisa Toh; Koji Nakagawa; Yoichi Takaya; Hiromi Matsubara; Hiroshi Ito
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

3.  Systematic Elucidation of the Mechanism of Genistein against Pulmonary Hypertension via Network Pharmacology Approach.

Authors:  Yucai Chen; Di Chen; Sijia Liu; Tianyi Yuan; Jian Guo; Lianhua Fang; Guanhua Du
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 5.923

4.  Nocturnal hypercapnia with daytime normocapnia in patients with advanced pulmonary arterial hypertension awaiting lung transplantation.

Authors:  Yoshinari Nakatsuka; Toyofumi Chen-Yoshikawa; Hideyuki Kinoshita; Akihiro Aoyama; Hiroyasu Kubo; Kimihiko Murase; Satoshi Hamada; Hirofumi Takeyama; Takuma Minami; Naomi Takahashi; Kiminobu Tanizawa; Tomohiro Handa; Toyohiro Hirai; Hiroshi Date; Kazuo Chin
Journal:  PLoS One       Date:  2020-04-15       Impact factor: 3.240

5.  Dose-related Effects of Resveratrol in Different Models of Pulmonary Arterial Hypertension: A Systematic Review.

Authors:  Andressa C Ferreira; Jerdianny S Serejo; Rafael Durans; Jadna M Pereira Costa; Antonio W S Maciel; Adeilson S M Vieira; Carlos A A Dias-Filho; Carlos J Dias; Maria R Q Bomfim; Cristiano T Mostarda; Janaina de O Brito-Monzani
Journal:  Curr Cardiol Rev       Date:  2020

6.  Nitric Oxide Stroke Volume Index as a New Hemodynamic Prognostic Parameter for Patients with Pulmonary Arterial Hypertension.

Authors:  Karolina Barańska-Pawełczak; Celina Wojciechowska; Mariusz Opara; Wojciech Jacheć
Journal:  J Clin Med       Date:  2020-09-11       Impact factor: 4.241

7.  Longitudinal changes in risk status in pulmonary arterial hypertension.

Authors:  Habib Bouzina; Göran Rådegran; Oisin Butler; Roger Hesselstrand; Clara Hjalmarsson; Katsiaryna Holl; Kjell Jansson; Rogier Klok; Stefan Söderberg; Barbro Kjellström
Journal:  ESC Heart Fail       Date:  2020-12-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.